K
Kevin Hudson
Researcher at AstraZeneca
Publications - 31
Citations - 1260
Kevin Hudson is an academic researcher from AstraZeneca. The author has contributed to research in topics: PI3K/AKT/mTOR pathway & Receptor tyrosine kinase. The author has an hindex of 16, co-authored 31 publications receiving 1093 citations. Previous affiliations of Kevin Hudson include University of Leicester.
Papers
More filters
Journal ArticleDOI
Activation of protein kinase B beta and gamma isoforms by insulin in vivo and by 3-phosphoinositide-dependent protein kinase-1 in vitro: comparison with protein kinase B alpha.
TL;DR: PKBgamma which had been activated by PDK1 possessed a substrate specificity identical with that of PKBalpha and PKBbeta towards a range of peptides, and was the major isoform activated by insulin in rat L6 myotubes (a skeletal-muscle cell line).
Journal ArticleDOI
Design and synthesis of novel lactate dehydrogenase A inhibitors by fragment-based lead generation.
Richard A. Ward,Claire Brassington,Alexander L. Breeze,Alessandro T. Caputo,Susan E. Critchlow,Gareth M. Davies,Louise Goodwin,Giles Hassall,Ryan Greenwood,Geoffrey A. Holdgate,Michael Mrosek,Richard A. Norman,Stuart E. Pearson,Jonathan Tart,Julie A. Tucker,Martin Vogtherr,David Whittaker,Jonathan Wingfield,Jon Winter,Kevin Hudson +19 more
TL;DR: Progress using fragment-based lead generation (FBLG), assisted by X-ray crystallography to develop small molecule LDHA inhibitors, which were identified through NMR and SPR screening and optimized into lead compounds with nanomolar binding affinities via fragment linking.
Journal ArticleDOI
Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS.
Sarah Ross,Alexey S. Revenko,Lyndsey Hanson,Rebecca Ellston,Anna Staniszewska,Nicky Whalley,Sanjay K. Pandey,Mitchell Revill,Claire Rooney,Linda K. Buckett,Stephanie Klein,Kevin Hudson,Brett P. Monia,Michael Zinda,David C. Blakey,Paul Lyne,A. Robert MacLeod +16 more
TL;DR: The safety of this approach was demonstrated in mice and monkeys with KRAS ASOs that produced robust target knockdown in a broad set of tissues without any adverse effects, and data suggest that AZD4785 is an attractive therapeutic for the treatment of KRAS-driven human cancers and warrants further development.
Journal ArticleDOI
LCR/MEL: a versatile system for high-level expression of heterologous proteins in erythroid cells.
Maurice Ronald Charles Needham,Clare Gooding,Kevin Hudson,Michael Antoniou,Frank Grosveld,Melvyn Hollis +5 more
TL;DR: The utility of the LCR/MEL cell system is demonstrated by the expression of growth hormone at high levels (greater than 100 mg/l) 7 days after induction, and it is possible to obtain clones with stable high-level expression within 3-4 weeks after transfection.
Journal ArticleDOI
Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL.
Tabea Erdmann,Pavel Klener,Pavel Klener,James T. Lynch,Michael Grau,Petra Vockova,Petra Vockova,Jan Molinsky,Jan Molinsky,Diana Tuskova,Diana Tuskova,Kevin Hudson,Urszula M. Polanska,Michael Grondine,Michele Mayo,Beiying Dai,Matthias Pfeifer,Kristian Erdmann,Daniela Schwammbach,Myroslav Zapukhlyak,Annette M. Staiger,Annette M. Staiger,German Ott,Wolfgang E. Berdel,Barry R. Davies,Francisco Cruzalegui,Marek Trneny,Marek Trneny,Peter Lenz,Simon T. Barry,Georg Lenz +30 more
TL;DR: The data suggest that patients should be stratified according to their oncogenic dependencies when treated with PI3K and AKT inhibitors when treating DLBCLs irrespective of their molecular subtype.